-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Initiates Coverage On Legend Biotech with Outperform Rating, Announces Price Target of $75

Benzinga·01/07/2026 15:39:50
Listen to the news
Oppenheimer analyst Trevor Allred initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Outperform rating and announces Price Target of $75.